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What is the current scientific knowledge on this subject? 
For patients with severe chronic obstructive pulmonary disease (COPD), inhaled preventer therapy 
reduces exacerbations of COPD.  Hence, when a patient with COPD is discharged from hospital, it is 
assumed that they continue their treatment to avoid re-admission. However, objective adherence, 
including technique of use, to inhaler therapy via the DiskusTM has not been previously studied in this 
patient population. 
What does the study add to the field? 
Using an acoustic based system to quantify when and how a DiskusTM inhaler has been used, this 
study identified that the Actual Adherence over the study was 22.9% of what would be expected if all 
the doses had been taken correctly and on time. Only 7% of the study population had an Actual 
Adherence over 80%. Adherence was negatively influenced by impairment in cognitive function and 
the degree of airways obstruction. 
 
"This article has an online data supplement, which is accessible from this issue's table of content 
online at www.atsjournals.org" 
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ABSTRACT 
Rationale 
Objective adherence to inhaled therapy by patients with COPD has not been reported. 
Objectives 
The aim of this study was to objectively quantify adherence to preventer DiskusTM inhaler therapy by 
patients with COPD with an electronic audio recording device (INCA
TM
).   
Methods 
This was a prospective observational study.  On discharge from hospital patients were given a 
salmeterol/fluticasone inhaler with an INCA
TM
 device attached.  Analysis of this audio quantified the 
frequency and proficiency of inhaler use.  
Measurements and Main Results  
COPD patients (n=265) were recruited.  The mean age 71 years, mean Forced Expiratory Volume in 
1-second 1.3 Litres, and 80% had evidence of mild/moderate cognitive impairment.  
By combining time of use, interval between doses and critical technique errors, thus incorporating 
both intentional and unintentional non-adherence, a measure “Actual Adherence” was calculated. 
Mean Actual Adherence was 22.9% of that expected if the doses were taken correctly and on time. 
Seven percent had an Actual Adherence>80%.  Hierarchical clustering found three equally sized well-
separated clusters corresponding to distinct patterns: Cluster 1 (34%) had low inhaler use  and high 
error rates, Cluster 2 (31%) had high inhaler use and high error rates, and Cluster 3 (30%) had overall 
good adherence. Lung function and co-morbidities were predictive of poor technique, while age and 
cognition with poor lung function distinguished those with poor adherence  and frequent errors in 
technique. 
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Conclusion 
These data may inform clinicians both in understanding why a prescribed inhaler is not effective and 
to devise strategies to promote adherence in COPD.  
Word Count = 247  
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INTRODUCTION 
Chronic Obstructive Pulmonary Disease (COPD) is a common chronic condition characterised by 
airflow limitation, which can be controlled with inhaled corticosteroids (ICS) (1). Prior studies, have 
shown that between 30 to 60% of patients do not regularly collect their prescriptions (2). Some studies 
have also reported poor inhaler adherence in hospitalised patients (3-5).   In addition, it is recognised 
that inhaler technique is poor among patients with COPD, which means that even when the 
medication is taken, a clinical response may not be achieved (6,7).  
Some of the current techniques for monitoring adherence include patient self-report and pharmacy 
refill records; however, these techniques are limited. With self-report some patients may have 
difficulty remembering medication use, while pharmacy refill records provide information on whether 
the prescription has been filled and not whether the individual has actually taken the medication.  
Electronic monitors can objectively assess inhaler adherence as seen in several published papers (8-
11).  Most electronic monitors used on inhalers report when the inhaler has been used (intentional 
adherence). We developed a device, INCA
TM 
(12), which assesses inhaler use over time by recording 
the audio associated with inhaler use. Analysis of the audio data allows inhaler technique errors 
(which may be considered as un-intentional non-adherence) to be identified.  In particular, audio 
analysis can identify errors such as failing to prime the inhaler, dispersing the medication by 
exhalation into the inhaler after priming, or failing to generate a sufficient inhalation flow as well as 
other errors such as dose dumping (13,14).  As the acoustic features of inhalation are highly reflective 
of objectively measured peak inspiratory flow, analysis of the audio recorded to the device can 
precisely assess medication delivery over time (13,15,16). In addition to providing an assessment of 
the proficiency of use, analysis of the recorded files provides information on the time of use and the 
interval between doses (12).  Hence, this technology allows the identification and characterisation of 
an individual’s inhaler use and technique over time (both intentional and unintentional non-
adherence).  To our knowledge no study on inhaler adherence in COPD, assessed by electronic 
recording devices, has been previously conducted. 
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In a landmark study, Vestbo and colleagues found that the least adherent patients in a clinical trial of 
patients with COPD randomised to receive salmeterol/fluticasone or placebo medication, had higher 
mortality and hospital readmission rates (17).  This association was independent of the study 
intervention and suggests that poor adherence is associated with critically important but yet 
unidentified factors other than simply not taking the medication.  Hence, it is important to both 
quantify inhaler adherence and also to understand the determinants of adherence among this 
population.  The objective of this study was to describe the patterns and the determinants of adherence 
to a commonly used preventer inhaler, salmeterol/fluticasone Diskus ™ inhaler, by patients with 
COPD.  
Some of the results of these studies have been previously reported in the form of an abstract (18). 
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METHODS  
Study design and Setting  
This was a prospective observational study of adherence to a regularly prescribed combination long 
acting beta-agonist/inhaled corticosteroid inhaler by patients with COPD following discharge from 
hospital. The study was performed in a single centre in the Republic of Ireland and was approved by 
the Beaumont Hospital Ethical (medical Research) Committee, Dublin, Ireland.  The study period was 
from February 2012 to February 2016.  Due to a lack of funding there was a gap in recruitment from 
June 2012 to January 2014. 
Participants  
Consecutive patients admitted to hospital for any reason were screened. Eligibility criteria included 
those who had a known diagnosis of COPD (obstructive spirometry, FEV1/FVC<70% or FEV1<80%), 
(1) age over 40 years, a smoking history, already prescribed salmeterol/fluticasone Diskus™ inhaler 
and who had an exacerbation of COPD in the previous year.  Eligible patients were approached and 
those who agreed to participate provided written informed consent.  
Variables Collected 
At recruitment, data was collected relating to patient age, sex, body mass index (BMI), smoking 
history, salmeterol/fluticasone dose and reason for admission.  
Reason for admission 
For this study, reason for admission was divided into two categories 1. Hospital Admission for COPD 
exacerbation and 2. Hospital Admission not related to COPD, as those admitted due to a COPD 
exacerbation would likely be considered to have more motivation to use an inhaler on discharge.   A 
COPD exacerbation was defined by a worsening of symptoms (shortness of breath, cough) requiring 
steroids and antibiotics.  Patients categorised as “Hospital Admission not related to COPD” included 
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those with a previous diagnosis of COPD who were admitted to hospital for an unrelated cause (i.e. 
surgical admission).  
 
Disease Severity 
To evaluate COPD severity, data on the number of COPD admissions in the previous year and 
pulmonary function (FEV1 (L) and % predicted) was collected and Cough Peak Expiratory Flow 
(cough PEF L/min, Mini-Wright Clement Clarke International LTD) was measured.  Patients were 
asked to complete the COPD Assessment Test (CAT) and to score their dyspnoea on the Medical 
Research Council (MRC) Dyspnoea Scale (1 to 5, 1 not limited and 5 unable to leave the home due to 
breathlessness).  With this information patients were classified into GOLD defined grades. (1).   
Personal Factors 
Co-morbid medical history (using the Charlson Co-Morbidity Score (19)) and the number of regular 
medications currently prescribed were  recorded.  Information on cognitive function (Montreal 
Cognitive Assessment, MoCA (20)) and psychological status (Hospital Anxiety Depression, HAD 
Score (21)) was recorded.  Health literacy was assessed using the European Health Literacy Survey 
(EHLS) (22) and patient’s beliefs in medicine were assessed by the Beliefs in Medication 
Questionnaire (BMQ, with a score >50 indicating negative beliefs in medicine (23)).   
In addition, data on the patient’s level of social support were collected. This included data pertaining 
to levels of governmental support for healthcare cost, social isolation (i.e. who lives at home alone, 
does the patient have a carer) and frailty (i.e. does the patient have a chairlift, a bedroom downstairs, 
meals delivered or need a carer). A categorical variable, “isolation”, was created as follows: 1 = Not 
Alone + Carer, 2 = Not Alone + No Carer, 3 = Alone + Carer, 4= Alone + No Carer; A categorical 
variable, “frailty” was created as follows: 1= Need a Chair lift, 2 = Bedroom Downstairs, 3 = 
Bedroom Downstairs/Need a Chair Lift + Meals delivered to the Home, and 4 = Bedroom 
Downstairs/Need a Chair Lift + Need of a Carer +/- Meals delivered home.  
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 Objective measurement of inhaler adherence and technique using the INCA
TM
 device 
An INCA
TM
 audio recording device was attached to a salmeterol/fluticasone Diskus
TM
 inhaler to 
objectively assess both time of use and technique of inhaler use.  Each time a patient opened their 
inhaler, a digital audio recording was made. These recordings were used to calculate the time of use, 
the interval between doses and the proficiency of inhaler use. Further details of the design and 
validation of the INCATM device have been previously reported (12,24).  
In hospital, patients were repeatedly shown how to use the inhaler by the ward staff each time the 
medication was dispensed, as per written Hospital Policy.  Inhaler proficiency was also assessed using 
a checklist on inhaler use, the Inhaler Proficiency Score (25,25,26). 
At recruitment, patients were given a new 60-dose salmeterol/fluticasone Diskus
TM
 inhaler with an 
attached INCA
TM
 device, for one month of use. On discharge, they were asked to continue using their 
inhaler as they had been shown, twice per day, and were told that between 26 and 30 days later they 
would be contacted and a courier would collect their inhaler. 
Calculation of adherence 
Two independent raters assessed the acoustic recordings for evidence of critical errors, as previously 
described (12-14).  The inter-rater agreement was 88.4%.  The raters did not have any involvement in 
any data analysis beyond rating the audio files.   Information on the time, interval between doses and 
technique of inhaler use were combined to calculate an area under the curve (AUC) metric, using a 
trapezoidal function.  This method of calculating adherence has previously been described (24).   
Initially, the AUC is calculated for the expected doses.  Following this, the AUC is calculated for the 
participant’s Attempted Adherence (audio files where there was evidence of drug priming), where 
non-attempted adherence demonstrate intentional non-adherence.  Removing doses where a critical 
technique error (i.e. failing to prime the inhaler, exhalation into the inhaler after priming and before 
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inhalation, or generating a low inspiratory flow) allows for calculation of the Actual Adherence, a 
combination of intentional and un-intentional non-adherence.   
 
 
Statistical Analysis 
All categorical variables were summarized using the number of observations, and percentage of 
patients.  Continuous variables were summarised using mean (SD) and ordinal data with median 
(IQR).   In cases where data were not normally distributed a log transformation was performed to 
achieve normality.  These data were analysed on a log scale and all results were back transformed.  
Between-group comparisons (e.g. reason for admission) were made with an unpaired t-test, ANOVA, 
Chi-squared test and Mann-Whitney test where appropriate.   Clustering was performed using an 
agglomerative hierarchical method, employing the wards-linkage function with squared Euclidian 
distance (27). This method was chosen over single-linkage clustering as it is more robust to noise in 
the data. Qualitatively similar results were also obtained using average-linkage clustering. The 
number of clusters was chosen from inspection of the cluster dendrogram.  Before clustering, 
variables were rescaled to have equal variance. This is required for algorithms employing a distance-
based metric.  A multinomial logistic regression was used to compare the different cluster groups in 
an attempt to predict cluster membership. 
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RESULTS 
Participants 
Over the study period, 265 patients consented to participate. Complete data on both baseline variables 
and electronically recorded adherence were available for 204 patients, see flow diagram, Figure 1.   
The characteristics of the patients are shown in Table 1.  The participants were elderly, mean age 71 
(SD=9.8) years with a mean FEV1 of 1.3L, 52% predicted.  In addition to COPD, they had a 
significant burden of other medical diseases with a mean Charlson co-morbidity score of 6 and 
further, were prescribed a median of 12 medications. One fourth were socially isolated (Isolation 
score> 2) and over a third had indices of frailty (Frailty score >2). Forty seven percent of the patients 
had evidence of mild cognitive impairment, MoCA score (19-24) and a further 33% had moderate 
cognitive impairment, with a MoCA score less than 19.  Other than features regarding the severity of 
COPD and indices of isolation/frailty, there were no significant differences in the characteristics of 
the patients admitted with an exacerbation of COPD and those admitted with another cause, see Table 
1.     
Adherence to a twice-daily preventer inhaler  
Using the AUC method (mentioned in the methods section) to calculate adherence the median (IQR) 
and mean (SD) Actual Adherence over the study period was 6% (42.0) and 22.9% (29.1) of what 
would be expected if all the doses had been taken correctly and on time. Only 7% of the study 
population had an Actual Adherence over 80%. There was no difference in the Actual Adherence 
between those who were discharged following an exacerbation of COPD, median (IQR) 6% (47%), 
mean (SD) 23.6% (29.4) and those COPD patients who had another reason for admission, median 
(IQR) 6% (32%) and mean (SD) 22.2% (29.2), p=0.74.   
Analysis of the digital audio data indicated that most patients intermittently or frequently made errors 
in inhaler handling in the month after hospital discharge, despite reasonably good inhaler technique on 
discharge with a mean inhaler checklist (IPS) score of 8 out of a possible 10. The most common error 
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made was low inhalation flow, (Peak Inspiratory Flow <35L/min); see Figure 2(d) and (e). Of the 
total 8133 audio files recorded to the INCATM device, this error occurred in 1941 (24%) inhalations.  
A further 984 (12%) made repeated short inhalations, termed multiple breaths.  Exhalation into the 
inhaler after priming the dose and before inhalation occurred in 277 events (3.4%), see Figure 2(a) 
and (c).  There were 30 audio files (0.03%) with evidence of more than 1 drug blister suggestive of 
dose wasting.  See Figure 3 for a distribution of inhaler technique errors. 
Analysis of the time of inhaler use indicated that, in contrast to the instruction that the inhaler was to 
be used twice per day twelve hours apart, most patients used the inhaler irregularly during the month 
following discharge.  There were both periods of excessive dosing (≥3 doses in 24 hours) and periods 
of missed doses (<2 doses in 24 hours), see Table 2 and Figure 2 (b), (d), (f) and (g).  Only 10 patients 
(5%) never attempted to use their inhaler and 29 patients (14%) used their inhaler less than 20% of the 
time (i.e. 2 to 3 times a week).   See Figure 4 for a summary of all adherence measures calculated. 
Patterns of inhaler use 
There was wide variability in inhaler use by the participants, as we have seen in other populations 
(12,24,28), therefore, we sought to characterise inhaler adherence by patterns.  Adherence patterns 
were characterised using clustering of the Attempted Adherence AUC and the technique error rate. 
Hierarchical clustering found three well-separated clusters of approximately equal size corresponding 
to distinct patterns of behaviour.  The characteristics of the three groups are shown in the online 
supplement, eTable 1.  Cluster 1, n=70 (34%), was characterised by low Attempted Adherence 
(mean=18%), intentional adherence, and high error rate (88%), un-intentional non-adherence. Cluster 
2, n=63 (31%), showed high Attempted Adherence (76%), intentional adherence, coupled with high 
error rate (73%), un-intentional non-adherence, leading to poor Actual Adherence (20%).  While 
Cluster 3, n=61 (30%), contained patients with better overall adherence, characterised by high 
Attempted Adherence (58%), intentional adherence and low error rate (8%), un-intentional non-
adherence. Ten patients with zero Attempted Adherence were excluded from the cluster analysis; see 
Table 3 and Figure 5.  
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Determinants of adherence  
Demographic and clinical measures predictive of cluster membership were investigated using a 
multinomial logistic regression, with good adherence (membership of Cluster 3) taken as the base 
outcome. Co-morbidity was strongly predictive of membership of both Clusters 1 and 2, suggesting a 
contribution to poor technique, while cough PEF, age and MoCA were predictive of membership of 
Cluster 1, corresponding to poor Attempted Adherence and high technique error rate. FEV1 was 
predictive of membership of cluster 2 (good Attempted Adherence, poor technique), but not cluster 1, 
suggesting lung function makes a contribution to technique errors in those with good Attempted 
Adherence.  See Table 4 for a summary of these results.  
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DISCUSSION 
In the month following discharge from hospital only 7% of patients with severe COPD used their 
preventer inhaler therapy regularly and with correct technique more than 80% of the time. By 
contrast, 31% used the inhaler regularly but made consistent errors, despite repeated instruction in 
hospital over 30% rarely used the inhaler and when they did so, they often used it incorrectly.  The 
major factors determining adherence were the presence of severely impaired lung function, which 
affected the inhalation flow, and the patient’s cognitive status which may have affected the patient’s 
ability to remember both when and how to use the inhaler.     
Re-admission following an exacerbation of COPD has become a measure of quality of care (29,30). 
Vestbo et al. found that hospital readmission with a COPD exacerbation was lower amongst those 
patients with better adherence (17).  It is essential, therefore, that strategies to reduce re-admission 
include emphasis on good adherence to maintenance inhaled medications and correct inhaler use. 
Currently, there is little information on the factors that influence adherence among COPD patients in 
this setting (following a hospital admission).  The design of successful adherence interventions 
requires a detailed understanding of the determinants of adherence in the population being targeted.  
Hence, we chose to study adherence in COPD patients being discharged from hospital. 
The determinants studied were based on the information in the published literature (17,31-36). One 
model, the COM B framework of adherence, groups adherence determinants under the themes of 
comprehension, opportunities and motivation (37). Hence, for COPD patients, their comprehension 
and capacity to remember and follow instructions, their motivation (which can be affected by the 
patient’s beliefs about medicine and illness), depression, social isolation, frailty and health status may 
impact on adherence (32,38-40). Lost opportunities for patient learning may also arise either because 
of poor healthcare professional communication, poor knowledge of inhaler handling leading to poor 
instruction, or a patient’s poor comprehension as a result of lower health literacy (41).  We used a 
variety of validated instruments to evaluate each of these themes and we included information on 
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measures of lung function, as we have previously shown that low inhalation flow is a common error 
in inhaler handling (12,24,28).   
Analysis of the information recorded to the INCA
TM
 device identified that most patients made errors 
in both inhaler use and technique. We used cluster analysis to categorise the patients into groups 
based on regularity and proficiency of use. Knowledge of these patterns of inhaler use could be used 
to develop personalised interventions to promote adherence. For example, those who use their inhaler 
well and on time need encouragement, while those who use the inhaler regularly but with incorrect 
technique would benefit from an intervention addressing this issue. Patients who are largely forgetful 
may benefit from a reminder based system (9) or an intervention such as motivational interviewing 
(42). 
The results of this study show that poor cognitive function is an important determinant of adherence. 
Cognitive impairment is increasingly being recognised in patients with COPD. For example, brain 
imaging studies have shown significant white matter pathology in the fronto-striatal regions, areas 
which impact on planning, problem solving, and prospective memory capacity (43,44). Patients with 
poor executive functioning often display a “knowing-doing discrepancy”. While they can report 
specific instructions they cannot translate these into specific behavioural and motor plans and activity. 
Hence, abnormalities in the executive and memory domain may influence adherence through poor 
recall of inhaler technique and not remembering to use their inhaler.  
The most common technique error identified in this study was low peak inspiratory flow, which 
occurred in 24% of all inhalations. For dry powder inhalers, the user is required to generate a 
sufficient inspiratory flow to de-agglomerate the particles for the inhaler to be effective. For many 
patients, particularly those experiencing increased hyperinflation during and after an exacerbation of 
COPD, it may not be possible to generate sufficient airflow for effective inhalation, leading to 
ineffective drug delivery. In our study, we found FEV1 and cough PEF to be predictive of a high 
technique error rate and thus poor overall adherence.  Low cough PEF could be the result of a number 
of aspects of severe COPD such as muscle weakness, airflow limitation and/or the effect of air 
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trapping (45,46)  Regardless of the exact mechanism, the low cough PEF seen in this cohort indicates 
the severity of the underlying lung condition and the ability of the patient to inhale with sufficient 
pressure to overcome the internal resistance of the dry powder inhaler.     
There are several limitations to this study. This was a single centre study observational study with no 
control arm and the findings of the study should be interpreted with this in mind.  Additionally, the 
majority (98%) of patients enrolled in this study held government sponsored health insurance, which 
is reflective of our cohort’s age group.  Whilst some patient characteristics of this cohort are quite 
different to those studied in randomised control trials of stable outpatient COPD (47), they are similar 
to those in recent observational cohort studies of hospital recruited COPD patients in the UK and 
USA(2,4,5,48,49).  Therefore, it is likely that our results are representative of similar patients in other 
health systems.  In addition, with regard to poor inspiratory flow, we are unable to say if this was due 
to impaired lung function or poor effort.  However, this was not the aim of this study and future 
qualitative studies looking at factors related to adherence and interventional studies will address this 
issue. 
As this study only analysed adherence over a one-month period, we do not know if adherence 
influences re-admission or if adherence patterns change over time. To address this we are performing 
a 3-month extension of this study to assess the relationship of adherence to future healthcare use.  A 
further limitation of this study was that only one pharmacological medication delivered by one device 
was studied, namely the salmeterol-fluticasone DiskusTM inhaler.  When we first developed the 
INCA
TM
 device we used it with the Diskus
TM
 device as, at the time, this was the most commonly used 
treatment for patients with COPD.  However, given that we were studying a behaviour that would 
likely be repeated by this patient group with other inhalers, we believe that the results can be 
generalised, although further study is warranted to investigate this.  We provided the adapted inhaler 
with the INCATM device attached and hence, deliberately concentrated on the implementation phase 
of adherence (50) In doing so, we may have not identified other determinants of adherence affecting 
the initiation or persistence phases of adherence, such as cost and access to pharmacy service to obtain 
medications(2). The technology is also limited by the fact that the patient has to return the inhaler and 
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device and the audio files have to be manually reviewed for the adherence to be calculated.  However, 
an automated algorithm that can analyse these audio files has been validated in a cohort of asthma 
patients and will be validated in a COPD cohort (14,51,52) Additionally, patients were aware that 
their adherence was being monitored for the month of the study which may lead to increased 
adherence.  However, adherence remained poor and suggests that adherence in a real world 
population may even be worse. 
There are several novel aspects to this study, including the measurement of adherence immediately 
following discharge from hospital, the description of novel patterns of adherence using analysis of 
data collected to a system that evaluated all aspects of inhaler use and the identification of novel 
determinants of adherence in this patient cohort.   Additionally, this study was performed in a ‘real 
world’ population.  However, this technology and methodology can also be utilised in a clinical trial 
setting and has potential use as an education tool to improve inhaler use and technique in clinical 
practice for patients and clinicians.   
There has been a proliferation of devices delivering inhaled medications in the last few years, which 
has challenged clinicians to train patients how to use theses devices correctly.  Pharmaceutical 
companies developing these devices should be mindful of creating easy to use fail-proof devices so as 
not to overburden patients and clinicians with the responsibility of learning the nuances of correct 
inhaler technique.  
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Conclusion 
The results of this study suggest that only 7% of patients with severe COPD had an adherence rate 
>80% following discharge from hospital. The major determinants of poor adherence were the 
presence of cognitive impairment, which affected the patient’s ability to remember to take the 
medication and severe hyperinflation, which affected the ability of the individual to generate 
sufficient inhalation flow and as a consequence resulted in impaired drug delivery.   
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TABLE 1:  The clinical features of the cohort including the demographics, COPD features, personal 
and socio-economic factors. Data for all patients in the cohort, as well as patients who were admitted 
to hospital with an exacerbation of COPD and those who had COPD but were admitted for other 
reasons are shown. All values are presented as mean (SD) except where indicated.  BMI, body mass 
index; FEV1, forced expiratory volume; Cough PEF, cough peak expiratory flow; CAT score, COPD 
assessment test ; MoCA, Montréal cognitive assessment; *Isolation Score and ^frailty scores were 
calculated as described in the methods section.  
  All Patients COPD 
Exacerbation 
Not COPD 
Exacerbation 
p value 
DEMOGRAPHICS ( n=265) (n=168) (n=97)   
Mean Age  70.6 (9.8) 70.2 (10.1) 71.2(9.2) 0.41 
Sex (% Female) 53% 57% 47% 0.15 
BMI 27.5 (6.6) 26.7 (6.5) 29.0 (6.6) 0.05 
Median Pack Years smoked (IQR) 47.0 (47.1) 47.0 (43.5) 47.0 (50.0) 0.99 
Currently smoking (%) 22% 25% 18% 0.22 
Salmeterol/fluticasone Dose (% 500mcg) 75% 77% 71% 0.28 
Inhaler Proficiency Score (range 0-10) 7.6 (1.6) 7.5 (1.5) 7.6 (1.7) 0.69 
DISEASE SEVERITY         
FEV1 (L) 1.3 (0.6) 1.2 (0.6) 1.5 (0.6) <0.01 
FEV1 (%) 51.7 (21.3) 49.0 (20.3) 57.7 (22.3) <0.01 
Cough PEF 159.6 
(99.2) 
150.60  
(87.7) 
173.1 
(112.3) 
0.09 
CAT score  20.5 (7.9) 21.2 (7.7) 19.3 (8.1) 0.06 
Number of COPD admissions in previous 
year 
1.3 (1.7) 1.8 (1.8) 0.7 (1.2) <0.01 
Median MRC dyspnoea score (IQR) 3.6 (1.1) 3.6 (1.1) 3.5 (1.1) 0.27 
Number in GOLD Grade (%) 
    A 
    B 
    C 
 
3 (1) 
56 (21) 
5 (2) 
 
0 (0) 
0 (0) 
4 (2) 
 
3 (3) 
56 (58) 
1 (1) 
 
0.02 
<0.01 
0.47 
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    D 201 (76) 164 (98) 37 (38) <0.01 
PERSONAL FACTORS         
Charlson Co-Morbidity 5.9 (1.8) 5.7 (1.7) 6.2 (2.0) 0.06 
Median No. of Regular Medications (IQR) 12 (7) 11 (8) 12 (7) 0.11 
Median No. of Nebulised Treatment (IQR) 1 (1.5) 1 (1) 1 (1) <0.01 
MoCA score (range  0-30) 20.2 (6.2) 19.9 (6.2) 20.7 (6.2) 0.36 
HADS Total score (range 0-14) 12.9 (7.5) 12.8 (7.5) 13.0 (7.5) 0.81 
Anxiety component of HADS (range 0-7) 6.9 (4.6) 6.7 (4.4) 7.2 (4.9) 0.44 
Depression component of HADS (range 0-7) 5.6 (4.1) 5.5 (4.2) 5.8 (3.9) 0.51 
European Health Literacy Score (range 16- 80) 33.7 (10.7) 33.7 (10.1) 33.8 (11.6) 0.94 
Beliefs in Medicine Questionnaire (range 18-90) 52.0 (10.7) 52.2 (11.3) 51.9 (10.2) 0.89 
Median Isolation Score (IQR)* 2 (1) 2 (0) 2 (2) <0.01 
Patients with Government Sponsored Health 
Insurance (%) 
98% 98% 99% 0.56 
Median Frailty Score (IQR)^ 2 (2) 2 (2) 2 (2.5) 0.47 
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TABLE 2: Frequency of different types of errors based on analysis of the recordings made to the 
INCATM device over one month of use.  The data shown reflects the various ways that patients may 
misuse an inhaler.  Specifically, attempted doses represents audio files where the patient attempted to 
take their medication (i.e. evidence of drug priming). Technique errors included the following critical 
errors in inhaler handling: blistering but no inhalation, inhalation flow less than 35L/sec, multiple 
short inhalations and exhalation into the inhaler after priming. Extra dosing, is defined as 3 or more 
doses in a 24 hour period, missed doses as <2 doses in a 24 hour period.  The total number of errors 
and the median and mean rates are shown below.  
 Attempted 
Doses 
Technique 
Errors 
Extra Doses Missed Doses 
Total Number 8133 4103 778 4568 
Median per person 
(IQR) 
46 (32) 15 (27) 3 (4) 17 (27) 
Median Rate (IQR) 62.5 (49.5) 12 (34) 6.7 (13.3) 33.1 (40.7) 
Mean Rate% (SD) 59.4 (30) 24.3 (27.5) 10.7 (12.4) 38.6 (26.7) 
Number of people 
(%) with >20% & 
<50% Mean Rate 
69 (34) 50 (24) 30 (15) 68 (33) 
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TABLE 3:  Mean (SD) of different adherence measures calculated from the INCATM device for the 
three clusters was calculated.  p values are obtained from one-way ANOVA of each variable across 
the three groups.  Cluster 1 were patients with poor Attempted Adherence and poor inhaler technique.  
Cluster 2 were patients with good Attempted Adherence and poor inhaler technique.  Cluster 3 were 
patients with good Attempted Adherence and good inhaler technique. 
 
 
 
 
  CLUSTER 1 
Poor Attempted 
Poor Technique 
CLUSTER 2 
Good Attempted 
Poor Technique 
CLUSTER 3 
Good Attempted 
Good Technique 
  
  n=70 n=63 n=61 P value 
ADHERENCE      
Actual Adherence (%) 1.73 (2.77) 19.5(19.6) 54.6 (28.5) <0.01 
Attempted Adherence (%) 18.1 (13.5) 76.1 (16.7) 58.5 (29.2) <0.01 
Technique Error Rate (%) 88.1 (17.2) 73.2 (24.8) 7.72 (8.63) <0.01 
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TABLE 4:  Multinomial logistic regression of adherence cluster membership against demographic 
and clinical factors. The reference category is good adherence (cluster 3). All variables have been 
standardised to unit variance to enable comparison of effect sizes. The coefficients represent the 
change in log-odds of cluster membership per unit increase in the associated variable. Overall the 
model fit was highly significant (Likelihood-Ratio Chi-square test, p <0.00005, pseudo-R2=0.204).  
Adherence Cluster Group Variable 
Relative Risk 
Ratio Std. Err. p value 
     
Cluster 1     
Poor Attempted MoCA 0.508 0.175 0.049 
Poor Technique Cough PEF 0.21 0.089 <0.001 
 FEV1 1.263 0.408 0.47 
 Co-Morbidity 4.279 2.026 0.002 
 Age 0.352 0.155 0.018 
 Constant 1.598 0.552 0.174 
     
Cluster 2     
Good Attempted MoCA 0.786 0.274 0.489 
Poor Technique Cough PEF 0.728 0.234 0.322 
 FEV1 0.536 0.166 0.045 
 Co-Morbidity 3.458 1.609 0.008 
 Age 0.604 0.263 0.246 
 Constant 1.509 0.51 0.224 
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FIGURE LEGENDS 
 
FIGURE 1: Study Flow:  During the study period, 265 patients with COPD were recruited.  Due to 
lost devices, device failures and patients passing away, there was adherence data on 204 patients. 
FIGURE 2: Examples of Different Inhaler use Figure (a) is an example of an inhaler returned from 
a patient who persistently exhaled into the device before inhaling, introducing moisture into the 
mouthpiece. The image clearly shows clumped drug deposition in the mouth piece, i.e. wasted 
medication.  Figures (b) to (g) are graphical representations of adherence data collected from the 
INCATM device over time (hours of the day on the y-axis and date on the x-axis).  Each mark on the 
graph indicates a dose taken; a green dot indicates good technique while an orange diamond indicates 
poor inhaler technique.  Figure (b) is a patient who was given the adapted inhaler for the day before 
discharge.  Following their discharge home this patient, for the most part, only took their medication 
once daily. Figure (c) is the adherence data for the patient who made the persistent error of exhaling 
into the inhaler after drug priming and before inhalation leading to drug clumping (a).  Figure (d) is an 
example of a patient who was overusing their inhaler, although with poor technique (low inspiratory 
flow) and then subsequently stopped using their inhaler for several weeks.  Figure (e) is a patient who 
took their inhaler every day with good interval between doses but with a persistent technique error, 
low peak inspiratory flow.  Figure (f) is an example of a patient who rarely took their medication, and 
when they did it was with poor inspiratory flow.  Figure (g) is an example of a patient who took their 
inhaler regularly and correctly for several days and then just stopped taking their medication for 2 
weeks. 
FIGURE 3:  Inhaler Technique Errors.  The most common technique error in this cohort of COPD 
patients was low peak inspiratory flow (PIF) followed by multiple inhalations (i.e. poor breath hold) 
and multiple errors (i.e. more than one error in an audio file). 
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FIGURE 4: Different Adherence Measures Calculated.  Figure (a) displays the difference in 
adherence calculated from the dose counter (Average Adherence) and the measures from the INCATM 
device, the Attempted Adherence (how frequently the patient tried to take their inhaler) and the 
Actual Adherence (accounting for time of use, interval between doses and technique of use).  There 
was a significant difference between the Average Adherence and the Actual Adherence, p<0.01.  
There was a significant difference between the Average Adherence and the Attempted Adherence, 
p<0.01, due to patients performing multiple blisters in one dose and dose dumping.  Figure (b) 
displays the high levels of missed doses, over dose and technique errors in this cohort of COPD 
patients. (*p<0.01) 
FIGURE 5: Different Inhaler Use Patterns.  Figure (a) is a dendrogram resulting from the cluster 
analysis using Ward’s method in 204 patients with COPD leading to 3 major clusters.  Figure (b) is a 
distribution of the three clusters based on Attempted Adherence and technique error rate.  Cluster 1 
represents patients with poor Attempted Adherence and high technique error rate, leading to a low 
Actual Adherence.  Cluster 2 represents patients with good Attempted Adherence and high technique 
error rate (i.e. Figure 2(e)).  Cluster 3 represents patients with good Attempted Adherence and low 
technique error rate leading to a high Actual Adherence.   
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FIGURE 1: Study Flow:  During the study period, 265 patients with COPD were recruited.  Due to lost 
devices, device failures and patients passing away, there was adherence data on 204 patients.  
Figure 1  
254x158mm (128 x 128 DPI)  
 
 
Page 31 of 38  AJRCCM Articles in Press. Published on 13-July-2016 as 10.1164/rccm.201604-0733OC 
 Copyright © 2016 by the American Thoracic Society 
  
 
 
FIGURE 2: Examples of Different Inhaler use Figure (a) is an example of an inhaler returned from a patient 
who persistently exhaled into the device before inhaling, introducing moisture into the mouthpiece. The 
image clearly shows clumped drug deposition in the mouth piece, i.e. wasted medication.  Figures (b) to (g) 
are graphical representations of adherence data collected from the INCATM device over time (hours of the 
day on the y-axis and date on the x-axis).  Each mark on the graph indicates a dose taken; a green dot 
indicates good technique while an orange diamond indicates poor inhaler technique.  Figure (b) is a patient 
who was given the adapted inhaler for the day before discharge.  Following their discharge home this 
patient, for the most part, only took their medication once daily. Figure (c) is the adherence data for the 
patient who made the persistent error of exhaling into the inhaler after drug priming and before inhalation 
leading to drug clumping (a).  Figure (d) is an example of a patient who was overusing their inhaler, 
although with poor technique (low inspiratory flow) and then subsequently stopped using their inhaler for 
several weeks.  Figure (e) is a patient who took their inhaler every day with good interval between doses 
but with a persistent technique error, low peak inspiratory flow.  Figure (f) is an example of a patient who 
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rarely took their medication, and when they did it was with poor inspiratory flow.  Figure (g) is an example 
of a patient who took their inhaler regularly and correctly for several days and then just stopped taking their 
medication for 2 weeks.  
Figure 2  
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FIGURE 3:  Inhaler Technique Errors.  The most common technique error in this cohort of COPD patients 
was low peak inspiratory flow (PIF) followed by multiple inhalations (i.e. poor breath hold) and multiple 
errors (i.e. more than one error in an audio file).  
Figure 3  
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FIGURE 4: Different Adherence Measures Calculated.  Figure (a) displays the difference in adherence 
calculated from the dose counter (Average Adherence) and the measures from the INCATM device, the 
Attempted Adherence (how frequently the patient tried to take their inhaler) and the Actual Adherence 
(accounting for time of use, interval between doses and technique of use).  There was a significant 
difference between the Average Adherence and the Actual Adherence, p<0.01.  There was a significant 
difference between the Average Adherence and the Attempted Adherence, p<0.01, due to patients 
performing multiple blisters in one dose and dose dumping.  Figure (b) displays the high levels of missed 
doses, over dose and technique errors in this cohort of COPD patients. (*p<0.01)  
Figure 4  
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FIGURE 5: Different Inhaler Use Patterns.  Figure (a) is a dendrogram resulting from the cluster analysis 
using Ward’s method in 204 patients with COPD leading to 3 major clusters.  Figure (b) is a distribution of 
the three clusters based on Attempted Adherence and technique error rate.  Cluster 1 represents patients 
with poor Attempted Adherence and high technique error rate, leading to a low Actual Adherence.  Cluster 2 
represents patients with good Attempted Adherence and high technique error rate (i.e. Figure 2(e)).  Cluster 
3 represents patients with good Attempted Adherence and low technique error rate leading to a high Actual 
Adherence.    
Figure 5  
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ONLINE SUPPLIMENTARY MATERIAL 1 
eTABLE 1: The clinical features of the three clusters including the demographics, COPD 
features, personal and socio-economic factors. All values are presented as mean (SD) except 
where indicated.  BMI, body mass index; FEV1, forced expiratory volume; Cough PEFR, 
cough peak expiratory flow rate; CAT score, COPD assessment test ; MoCA, Montréal 
cognitive assessment; *Isolation Score and ^frailty scores were calculated as described in the 
methods section. 
  
 
 
CLUSTER 
1 
Poor 
Attempted 
Poor 
Technique 
CLUSTER 
2 
Good 
Attempted 
Poor 
Technique 
CLUSTER 
3 
Good 
Attempted 
Good 
Technique 
 
 
 
 
p value 
DEMOGRAPHICS ( n=70) (n=63) (n=61)   
Mean Age  71.4 (9.3) 69.2 (8.9) 67.6 (9.8) 0.49 
Sex (% Female) 61% 43% 51% 0.10 
BMI 27.0 (7.0) 27.6 (7.2) 28.1 (5.4) 0.05 
Pack Years smoked 53.9 (43.5) 64.8 (50.5) 50.7 (30.4) 0.75 
Currently smoking (%) 29% 23% 15% 0.19 
Salmeterol/fluticasone Dose (% 500mcg) 67% 78% 82% 0.14 
Inhaler Proficiency Score (range 0-10) 7.2 (1.7) 7.6 (1.7) 8.0 (1.4) 0.20 
DISEASE SEVERITY         
FEV1 (L) 1.3 (0.6) 1.2 (0.7) 1.4 (0.7) 0.35 
FEV1 (%) 54.7 (22.4) 48.3 (20.4) 55.1 (23.6) 0.63 
Cough PEFR 121.6 
(81.0) 
184.8  
(111.3) 
199.8 
(108.8) 
<0.01 
CAT score  20.6 (8.1) 18.9 (7.0) 22.4 (7.6) 0.56 
Number of COPD admissions in previous 
year 
1.6 (1.7) 1.2 (1.8) 1.3 (1.5) 0.09 
Median MRC dyspnoea score (IQR) 3 (1) 4 (1) 4 (1) 0.25 
Number in GOLD Grade (%) 
    A 
    B 
 
0 (0) 
14 (20) 
 
1 (2) 
10 (15) 
 
0 (0) 
12 (20) 
 
0.33 
0.76 
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    C 
    D 
1 (2) 
55 (78) 
1 (2) 
51 (81) 
0 (0) 
49 (80) 
0.60 
0.93 
PERSONAL FACTORS         
Charlson Co-Morbidity 6.2 (2.1) 5.9 (1.3) 5.4 (1.8) 0.05 
Median No. of Regular Medications (IQR) 12 (6) 12 (7) 11 (9) 0.96 
Median No. of Nebulisers used (IQR) 1 (1) 1 (0.5) 1 (1) 0.36 
MoCA score (range  0-30) 18.1 (7.0) 22.1 (4.6) 23.1 (4.7) <0.01 
HADS Total score (range 0-14) 13.0 (7.3) 10.9 (6.1) 13.5 (7.6) 0.69 
Anxiety component of HADS (range 0-7) 7.0 (4.5) 6.4 (4.3) 7.0 (4.4) 0.69 
Depression component of HADS (range 0-7) 5.9 (4.4) 4.6 (2.9) 5.8 (4.1) 0.92 
European Health Literacy Score (range 16- 80) 36.8 (11.3) 31.6 (8.0) 32.8 (10.5) 0.61 
Beliefs in Medicine Questionnaire (range 18-90) 49.9 (10.3) 53.9 (9.8) 50.5 (11.8) 0.66 
SOCIO-ECONOMIC DETAILS         
Patients Living Alone (%) 26% 26% 19% 0.63 
Patients with a Carer (%) 16% 20% 18% 0.80 
Number of Floors in Home  1.8 (0.5) 1.9 (0.4) 1.8 (0.5) 0.41 
Patients with a Stair Lift (%) 20% 24% 14% 0.55 
Patients with Downstairs Bathroom (%) 29% 24% 27% 0.77 
Patients with Downstairs Bedroom (%) 52% 41% 47% 0.80 
Patients who get Meals Delivered (%) 3% 4% 4% 0.99 
Median Isolation Score (IQR)* 2 (1) 2 (1) 2 (0) <0.01 
Patients Isolation Score* >2 (%) 26% 27% 19% 0.59 
Patients with Government Sponsored Health 
Insurance (%) 
100% 100% 95% 0.86 
Median Frailty Score (IQR)^ 2 (1) 2 (3) 2 (2) 0.31 
Patients Frailty Score >2 (%) 14% 35% 42% 0.13 
 
Page 38 of 38 AJRCCM Articles in Press. Published on 13-July-2016 as 10.1164/rccm.201604-0733OC 
 Copyright © 2016 by the American Thoracic Society 
